Geron Corporation

Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients. To learn more, visit Geron’s Community Guidelines: